chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pneumonia; COPD exacerbation; herpes zoster; Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. The patient's medical history and concomitant medications were not provided. Her concurrent condition included chronic obstructive pulmonary disease (COPD). In or around 28-MAY-2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dosage, route, lot number and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster).  Shortly after receiving zoster vaccine live (ZOSTAVAX) (date unknown in 2017), the patient suffered from COPD exacerbation and pneumonia, which required hospitalization. Additionally, shortly after receiving zoster vaccine live (ZOSTAVAX) (date unknown in 2017), the patient also suffered from lesions and was diagnosed with herpes zoster.  As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms had resulted in physical limitations not present prior to using the product. The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of the company wrongful conduct, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of the company's conduct, the patient had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was reported as not recovered. The events were considered to be related to zoster vaccine live (ZOSTAVAX).   The events herpes zoster, COPD exacerbation and pneumonia were considered to be disabling. Upon internal review, the event pneumonia was determined to be medically significant.
Redness, swollen in RA, nausea, dry heaving, high temp., HA. Pt states she went to doctor, he gave her some histamine and pres. for antibiotics.
After receiving the Fluzone + Pneumovax 23 vaccinations the patient complained of chest + back pain. EMS was called + patient transported to the ER.
Information has been received concerning a female patient "maybe college-age" with unspecified medical history, drug reactions or allergies, who in 2008 was vaccinated with a dose of GARDASIL (route and lot # unknown). Concomitant medication unspecified. On 17-NOV-2009, a news station reported that the patient reported that she received GARDASIL and on an unspecified date she became tired all of a sudden, she also suddenly developed lupus and her pancreas had to be taken out. She possibly might need chemotherapy in the future. Unspecified lab diagnostic studies performed. The patient sought unspecified medical attention. At the time of this report the patient had not recovered. Attempts are being made to verify the existence of an identifiable patient. No further information is available.
SWELLING OF THE LEFT ARM,  DIFFICULTY BENDING THE ELBOW, ITCH AND PAIN ON ARM.  SHE APPLIED VICKS ON THE INJECTED AREA AND ICE.
Pt w/ syncopal episode and dizziness approximately 10 mins after vaccination.  BP 105/59, HR 72, RR 16 -- > 110/68, 81.  Pt was hydrated and released by provider.  Pt was alert and oriented, speaks in full complete sentences, VSS.  No facial/mandible/tongue swelling.  NO stridor.  Pt feeling better.  Ambulated with steady gait.  Released from vaccination site with parents.  Instructed to follow w/ PMD.
I felt tired the day of the vaccine. The next morning woke up with a 101 degree fever and fatigue. Following day fever was gone but then headache, and nausea started. I am still having headaches, waves of nausea and fatigue  since getting vaccinated a week ago. It feels identical to when I had COVID in January. I also previously has severe headaches with my second vaccination back in 05/2021 but I did not report it. I feel that symptoms a week after vaccination are worth reporting so I am doing so now.
I have swollen lymph nodes at back of my neck (left side); left arm has been hurting like some joint pain feeling; I noted my shoulder (Left) being painful; Xray showed degenerative changes; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 36 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in deltoid left, administration date 14Jun2021 12:30 (Lot number: EW0179) at the age of 36 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Latex" (unspecified if ongoing); "COVID-19" (not ongoing), notes: if covid prior vaccination: Yes. Concomitant medication(s) included: BIOTIN taken for supplementation therapy (ongoing); VIT C taken for supplementation therapy (ongoing); PROBIOTICS taken for supplementation therapy (ongoing). Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EW0161, Location of injection: Arm Left, Vaccine Administration Time: 12:30 PM), administration date: 24May2021, when the patient was 36 years old, for COVID-19 immunization. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 20Sep2021 12:00, outcome "not recovered", described as "I have swollen lymph nodes at back of my neck (left side)"; VACCINATION SITE JOINT PAIN (non-serious) with onset 20Sep2021 12:00, outcome "not recovered", described as "left arm has been hurting like some joint pain feeling"; VACCINATION SITE PAIN (non-serious) with onset 2021, outcome "not recovered", described as "I noted my shoulder (Left) being painful"; DEGENERATIVE BONE DISEASE (non-serious) with onset 2021, outcome "not recovered", described as "Xray showed degenerative changes". The events "i have swollen lymph nodes at back of my neck (left side)" and "left arm has been hurting like some joint pain feeling" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of lymphadenopathy, vaccination site joint pain, vaccination site pain, degenerative bone disease.  Additional Information: Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Treatment received for the adverse event was Steroid injection, Tizanidine pills for 7 days. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not been tested for COVID-19. Patient provided information that Pfizer product had a casual effect to the adverse event. Vaccine was not Administered at a Facility. No Prior Vaccinations. No Patient Medical History. Family Medical History Relevant To AE(s) Father: Hypertension, DM2, Liver Disease; Mother: Hypertension. Stroke. Patient received new medication/other treatment/procedure which included Tizanidine 4mg CHS X7 days, Dexamethasone inj. given IM once. Patient reported it only gives me a little ease. I noticed my lymph nodes at the back of my neck (Left side) to be swollen as well.  Follow-up attempts are completed. No further information is expected.
25jul90 pt vax hepta B. 15-20 min aft vax pt devel n/v, diaphoresis, and dizziness which persisted for 21 hrs.  blood pressure and pulse were normal.  next day pt reported only local soreness at inject site.
Patient seemed to have a seizure lasting 1 minute, hitting head as he fell out of his seat.  He then became aware of surrounding.  Paramedics came and took patient to ambulance.
lightheadness starting 35 mins p/inject; slept for several hrs; upon awaking was fatigued & achy all over; 13JUN94 f/u rec'd 2nd dose on 18MAY94 3rd ds on 26MAY94 w/o incident;
Bell's Palsy; dry eyes; This is a spontaneous report from a contactable consumer (patient) or other non HCP.   A female patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot number and Expiry date was not reported) dose 2 via an unspecified route of administration on an unspecified date as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medication were not reported. The patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot number and Expiry date was not reported), via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunisation. On an unspecified date patient experienced Bells Palsy, dry eyes. it was reported that She was also reporting having dry eyes, which the caller clarifies related to her Bell's Palsy & she was not calling specifically questioning the dry eyes but more so the Bell's Palsy. Caller wants to know if Bell's Palsy is a reaction to the vaccine. She states she knows she was not the only one who came down with Bell's Palsy after the vaccine.  The outcome of the events was unknown.   The lot number for the vaccine, (BNT162B2), was not provided and will be requested during follow-up.
Night of receiving vaccine, patient experienced and is still experiencing severe pain, area is swollen, red, itching. On evening of patient took a hydrocodone. 2 days after started BENADRYL.
This spontaneous report was received from a nurse refers to unspecified number of patients of unknown age and unknown gender. On an unspecified date, the unspecified number of patients were vaccinated with doses of improperly stored GARDASIL (lot# K005881 with an expiry date of 14-JAN-2017). No adverse effects were reported. Additional information has been requested.
had the Pfizer Covid Vaccine than got Covid; had the Pfizer Covid Vaccine than got Covid; This is a spontaneous report from a contactable consumer(patient).  A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunisation.  The patient medical history and concomitant medications were not reported. The patient reported that she had the Covid Vaccine then got Covid.The Physicians said wait ninety days after for the Booster and she wanted to know whether it was okay.The event outcome was unknown.   Information on the lot/batch number has been requested.
Hives remained until Wednesday. After taking BENADRYL, MEDROL dosepak and applying BENADRYL cream, patient has recovered drastically but there are mild case of hives still remains.
This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (not been feeling well and it has been 30 days since first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (not been feeling well and it has been 30 days since first dose). At the time of the report, MALAISE (not been feeling well and it has been 30 days since first dose) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.Concomitant medication information was not provided by the reporter.Treatment information was not provided by the reporter.
Area on (L) arm tricep area approx. 5cm by 2 1/2cm redness & puffy.
c/o cold for 2 wks was taking ATB; still didn't feel any better also sore throat had devel;
Nausea, headache, muscle pain, shivering.  Had to stay in bed all day, I was very weak. No fever. Next day I felt better,, but a day later still not feeling well, although symptoms were milder. Third day I was ok.
Patient was given Adult Hep A instead of Pediatric/Adol HepA. No adverse event or reactions noted.
Red mark about the size of a 50 cent piece; Itching; A spontaneous report was received from a consumer concerning a, female patient, participating in the Moderna's COVID-19 vaccine (mRNA-1273) Emergency Use Program  who had experienced Red mark about the size of a 50 cent piece,  Itching.  The patient's medical history, is not provided by the reporter.  Concomitant medications were not reported.   The patient received their first of two planned dose of mRNA-1273 on 12Jan2021. On prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 in(Lot number: 041L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.  Experienced Red mark about the size of a 50 cent piece, Itching.   No lab data is reported by the reporter.   Action taken with mRNA-1273 in response to the events was not reported.     The outcome of events,Red mark about the size of a 50 cent piece,  Itching were unknown.   The reporter did not provide an assessment for the events Red mark about the size of a 50 cent piece,  Itching.  Since no Seriousness criteria is reported , hence the case is considered to be Non-serious.
arm and shoulder are still painful; Shoulder pain; Mobility decreased; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 84-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 13th December 2019, the patient received the 2nd dose of Shingrix. On an unknown date, less than 3 weeks after receiving Shingrix, the patient experienced pain in arm, shoulder pain and mobility decreased. On an unknown date, the outcome of the pain in arm, shoulder pain and mobility decreased were unknown.   It was unknown if the reporter considered the pain in arm, shoulder pain and mobility decreased to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported but could be 83 or 84 years. The patient experienced arm and shoulder pain after vaccination. The patient cannot lift arm very far after vaccination. The patient asked whether the event occurred is normal.
One week after last shot developed shingles.   treatment to date consist of at home methods to reduce pain and itching along path from back to center to edge of right breast.  All rash is on my right side.  Seven days since beginning of rash which proceeded by five days of back pain before realizing what was happening.  Tried acetaminophen for pain relieve but developed a rash on arms and legs with intense itching and had never had a reaction before to this medicine.  My immune system is not acting as it normally does.
After child received MedImmune LAIV child had mild reaction - small red area around (R) nostril - mom administered BENADRYL and no further reaction noted.
Low grade fever, chills, body aches, intense headache , excruciating eye pain and my hair hurt
6 month immunization given (DTAP) on 02/02/04.  Mom started noticing jerky movements within a couple of days of getting immunization. Diagnosed with infantile spasm/follow up neurology.
Swollen eyes; Face became red - red primarily in her cheeks; touches her face she feels it has a temperature; bit itchy on her cheek; This spontaneous case was reported by a consumer and describes the occurrence of EYE SWELLING (Swollen eyes), FLUSHING (Face became red - red primarily in her cheeks), PRURITUS (bit itchy on her cheek) and BODY TEMPERATURE INCREASED (touches her face she feels it has a temperature) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 12-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EYE SWELLING (Swollen eyes), FLUSHING (Face became red - red primarily in her cheeks), PRURITUS (bit itchy on her cheek) and BODY TEMPERATURE INCREASED (touches her face she feels it has a temperature). At the time of the report, EYE SWELLING (Swollen eyes), FLUSHING (Face became red - red primarily in her cheeks), PRURITUS (bit itchy on her cheek) and BODY TEMPERATURE INCREASED (touches her face she feels it has a temperature) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment details were provided.   Reporter did not allow further contact
Expired Shingrix administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 69-year-old male patient who received Herpes zoster (Shingrix) (batch number 74FB9, expiry date 17-MAR-2023) for prophylaxis.   On 22-MAR-2023, the patient received the 1st dose of Shingrix (right deltoid). On 22-MAR-2023, an unknown time after receiving Shingrix, the patient experienced expired vaccine used (Verbatim: Expired Shingrix administered). The outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 27-MAR-2023 The reporter consented to follow up.  The patient was administered an expired Shingrix vaccine inadvertently, which led to expired vaccine used. This case was 1 of 3 cases, reported by the same reporter.; Sender's Comments:  US-GSK-US2023046086:Same reporter US-GSK-US2023046092:Same reporter
Injection site red, warm, raised. Patient has swollen neck, red neck and upper chest, eyes swollen red and irritated, tickly throat. Advised BENADRYL & call P.C.P. MD advised BENADRYL 4 tablespoons every 4-6 hours.
I had flu-like symptoms after the 2nd dose for 4 days.    I got radiesse filler in my face 1/22/21 and about two days later developed facial swelling out of proportion to expected swelling
+ covid positive test; + covid positive test; rhonorrhea; sneezing; booster; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP) from product quality group.  A 65 year-old male patient received bnt162b2 (BNT162B2), administration date 08Oct2021 (Lot number: FF2589) at the age of 65 years as dose 3, (booster) single, administration date 16Feb2021 (Lot number: EL3247) as dose 2, single and administration date 26Jan2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: IMMUNISATION (medically significant) with onset 08Oct2021, outcome "unknown", described as "booster"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 10Jan2022, outcome "unknown" and all described as "+ covid positive test"; RHINORRHOEA (non-serious) with onset 10Jan2022, outcome "unknown", described as "rhonorrhea"; SNEEZING (non-serious) with onset 10Jan2022, outcome "unknown", described as "sneezing". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (10Jan2022) positive. It was unknown if therapeutic measures were taken as a result of vaccination failure, covid-19, rhinorrhoea, sneezing.  Clinical course: product: COVID 19, brand: Pfizer, brand unknown: False, lot unknown: False, dose number: 3 previous dose details: prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot unknown: False, prev dose, dose number: 2, prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot unknown: False, prev dose, dose number: 1. Did the patient receive any other vaccines within 4 weeks prior to the COVID vaccine: Unknown. Reported Event: + Covid positive test on 1/10 mild sx rhinorrhoea sneezing prior to vaccination, was the patient diagnosed with COVID-19?: Unknown, Covid test post vaccination: Covid test type post vaccination: Unknown, Covid test name post vaccination: unknown. Device Date : 18Jan2022.  No follow-up attempts are possible. No further information is expected.
About 4 days after receving the flu shot, I woke up with extreme pains in my joints and muscles.  The pain progressively got worse for 4 days.  I did not have a fever.  Since I was 5 weeks pregnant (after speaking to my OBGYN) she advised me to take Tylenol to relieve the pain, which helped make the pain somewhat manageable.
-Patient was seen at the ER; admitted one day.  Patient received epinephrine/ hydroxyzine/famotidine/albuterol.
No adverse event; Monovalent dose administered after the BUD to patient; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Monovalent dose administered after the BUD to patient) and NO ADVERSE EVENT (No adverse event) in a 33-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 059H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Mar-2022, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 24-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Monovalent dose administered after the BUD to patient). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Monovalent dose administered after the BUD to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Monovalent dose administered after the BUD to patient).    It was reported that it was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Patient ID was reported.  Concomitant product use was not provided by the reporter.  It was reported that 77 Monovalent doses administered after the BUD to patients 12 and up. Breakdown of doses were as follows- 37 doses from Lot 059H21, 26 doses from Lot 065K21A, and 12 doses from Lot 058A22-2A.  Treatment information was not provided.
At injection site, swollen, red warm lump moved down my arm / above the elbow; At injection site / red warm lump moved down my arm / above the elbow; At injection site / warm lump moved down my arm / above the elbow; At injection site / lump moved down my arm / above the elbow; I had flu like symptoms; Low fever for a couple of days; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced injection site swelling, injection site erythema, injection site warmth, injection site lump, influenza-like symptoms and fever. On an unknown date, the outcome of the injection site swelling, injection site erythema, injection site warmth and injection site lump were unknown and the outcome of the influenza-like symptoms and fever were recovered/resolved.   It was unknown if the reporter considered the injection site swelling, injection site erythema, injection site warmth, injection site lump, influenza-like symptoms and fever to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient was due for her 2nd Shingrix shot but had an adverse reaction so did not know if should go ahead. Adverse reaction was at the injection site. Swollen, red warm lump moved down her arm until it was just above the elbowby day 4. The patient also had flu like symptoms and low fever for a couple of days but her arm reaction seemed worrying. The patient had an antibodies test the other day to see if another shot was needed and it was more than 8.0 but did not know how to interpret. The reporter consented to follow up